Quiver News

AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System , a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures.

The ANTHEM™ Elbow Fracture System is designed to offer surgeons anatomically contoured plates to treat a variety of fractures, regardless of severity or complexity, with a simplified workflow.

Engineered to simplify surgical workflows while offering versatility, the ANTHEM™ Elbow Fracture System provides anatomically contoured plates tailored for distal humerus, proximal ulna, proximal radius, and coronoid fractures. With 14 plate families, 2.7mm and 3.5mm screw options, and anatomy-specific reduction instruments , the system empowers surgeons to treat even the most complex fracture patterns .

All plates in the portfolio feature polyaxial locking technology , to enable either fixed-angle trajectories or screw placement within a 40º cone of angulation , offering flexibility in accommodating fixation strategies.

“In the first clinical use of the ANTHEM™ Elbow Fracture System, I found the design to be both practical and reliable. The anatomically contoured plates fit well to the bone and supported fixation with minimal disruption of the triceps,” says Dr. Gary Updegrove, Penn State Health, Hershey, Pa. "The polyaxial locking holes, combined with calibrated drill guides, helped support precise screw placement and allowed me to achieve strong fixation while easily avoiding intra-articular penetration. As someone who specializes in complex elbow fracture surgery and upper extremity trauma care, I especially appreciated the flexibility of the system — with multiple plate families and screw options available, I could tailor the construct to match the complexity of each fracture pattern in this case. This is exactly the kind of thoughtful design that makes a difference in elbow trauma surgery.”

“The launch of the ANTHEM™ Elbow Fracture System marks another milestone in our commitment to advancing trauma care,” says John Mulchay, President of Orthopedics and Chief Commercial Officer at Globus Medical. “By delivering a comprehensive and intuitive solution for elbow fractures, we’re equipping surgeons with the tools they need to provide outstanding care and streamline procedures.”

The ANTHEM™ Elbow Fracture System is the latest addition to Globus Medical’s expanding Trauma Portfolio, reinforcing the company’s dedication to innovation and excellence in musculoskeletal care.

Learn more about the ANTHEM™ Elbow Fracture System: https://www.globusmedical.com/musculoskeletal-solutions/trauma/

About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com .

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Investor contact:
Brian Kearns
610-930-1800
[email protected]

Media contact:
Moran Chavez
[email protected]

TALLAHASSEE, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Capital City Bank Group, Inc. (NASDAQ: CCBG) announced today that it will release third quarter 2025 results on Tuesday, October 21, 2025, before the market opens. Upon release, investors may access a copy of the earnings results at the Company's Investor Relations website, investors.ccbg.com .

About Capital City Bank Group, Inc.
Capital City Bank Group, Inc. is one of the largest publicly traded financial holding companies headquartered in Florida and has approximately $4.3 billion in assets. We provide a full range of banking services, including traditional deposit and credit services, mortgage banking, asset management, trust, merchant services, bankcards, and securities brokerage services. Our bank subsidiary, Capital City Bank, was founded in 1895 and now has 62 banking offices and 107 ATMs/ITMs in Florida, Georgia and Alabama. For more information about Capital City Bank Group, Inc., visit www.ccbg.com .

For Information Contact:
Jep Larkin
Executive Vice President and Chief Financial Officer
850.402.8450

-   Expanding and accelerating HPC/AI strategy across multiple initiatives
-   Received confirmation from Clarington, Ohio power utility that all 570 MW of electrical capacity will be available by end of Q3 2026
-   Increased self-mining hashrate to 35.0 EH/s on continued deployment of SEALMINERs
-   Launched and commenced mass production of SEALMINER A3 series
-   Tydal, Norway and Jigmeling, Bhutan sites energization completed
-   New power pipeline of 300 MW in Niles, Ohio officially launched in September
-   First design of SEAL04 chips taped out and initial testing demonstrated sub-10 J/TH efficiency

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) (“ Bitdeer ” or the “ Company ”), a world-leading technology company for Bitcoin mining, today announced its unaudited mining and operations updates for September 2025.

Operational Update

• Self-mining: 452 Bitcoins mined, an increase of ~20.5% from August 2025 due to higher average self-mining hashrate from energization of SEALMINERs. 35.0 EH/s deployed. On track to reach 40 EH/s at the end of October. After October, Bitdeer will continue deploying SEALMINER mining rigs for self-mining and concurrently begin retiring all third-party, older-generation rigs to further enhance profitability and fleet efficiency.
• Mining Rig Manufacturing and R&D:
  • SEALMINER A2:
    • Total of 34.2 EH/s in mining rigs have been manufactured and an additional 2.8 EH/s are in final assembly as of end of September 2025.
    • Of the 34.2 EH/s mining rigs that have been manufactured:
      • External-sales: 6.1 EH/s of mining rigs have been shipped to external customers, including 0.1 EH/s that were shipped in September.
      • Self-mining:
        • 22.6 EH/s of mining rigs have been deployed in U.S., Tydal, Norway and Jigmeling, Bhutan, including 4.6 EH/s in September 2025.
        • 5.5 EH/s of mining rigs are in-transit to Bitdeer’s sites in Norway and Bhutan.
  • SEALMINER A3:
    • Launched in September, the A3 series includes four models:
      • Two air-cooling models A3 Air and A3 Pro Air, achieving a power efficiency of 12.5 J/TH ~ 14 J/TH and a hashrate of 260 TH/s ~ 290 TH/s.
      • Two hydro-cooling models A3 Hydro and A3 Pro Hydro, reaching a power efficiency of 12.5 J/TH ~ 13.5 J/TH and a hashrate of 500 TH/s ~ 660 TH/s.
      • Commenced mass production and expect initial deliveries/shipments in October 2025 for self-mining.
  • SEALMINER A4:
    • Planning two different chip designs of SEAL04 to ensure success.
    • The first SEAL04 chip tape out was completed in September and are currently under testing. Initial results from the early samples demonstrated sub-10 J/TH power efficiency at the chip level, though still above the 5 J/TH target.
    • Awaiting further sample testing to verify the feasibility of achieving the 5 J/TH chip-level power efficiency goal on the first SEAL04. Nevertheless, Bitdeer is now confident that the first SEAL04 chip is ready for mass production and will deliver significant power efficiency improvements.
    • The SEAL04 with the new architecture is still expected to reach a target chip level efficiency of 5 J/TH.
  • U.S. Manufacturing: Bitdeer’s U.S. factory is actively in planning and preparation.
• HPC/AI:
  • As of September, Bitdeer allowed its LOI (Letter of Intent) with its development partner to expire in order to significantly expand its direct role in the HPC/AI data center market. In conjunction, Bitdeer has initiated design and layout planning for the Clarington, Ohio site. The new data center will be suitable for Bitcoin mining, with core infrastructure designed from the start to enable easy conversion into an AI data center with redundancy and other critical design elements to ensure flexibility and scalability.
  • Actively recruiting US based in-house experts across multiple AI data center disciplines.
  • HPC/AI priority remains Clarington, Ohio, where the local utility has confirmed that the full 570 MW will be available by the end of Q3 2026—nearly a year earlier than prior expectations. Teams are targeting substation energization in the first half of 2027.
  • Bitdeer also plans to convert its 175 MW Tydal Phase 2 site into an AI data center with expected completion date of Q4 2026. This site is expected to support 164 MW of key IT load after applying various security redundancy considerations. During the conversion process, mining operations will be minimally impacted, as the Tydal, Phase 2 design had already incorporated potential conversion from Bitcoin mining to an AI data center. The capital expenditure required for this conversion will be significantly lower than the average cost of constructing a new AI data center in the U.S or Norway.
  • Bitdeer is also working on converting its Wenatchee 13 MW site into an AI data center with modular data center technology.
  • Bitdeer is also sourcing data center resources in Southeast Asia, either through rental arrangements or self-built facilities. By the end of 2026, Bitdeer expects to operate more than 200 MW of IT load dedicated to AI computing, the majority of which will be owned by Bitdeer. Bitdeer plans to pursue two business models in parallel or in combination — colocation services and AI factory operations.
  • Bitdeer sees sustained imbalance between the growing demand and limited supply of AI computing power, and expects it to extend through 2027. In the most optimistic scenario, Bitdeer plans to acquire GPUs for cloud deployment and convert the entire 200 MW of IT load into an AI factory, potentially generating an annualized revenue run-rate (ARR) exceeding US$2 billion at the end of 2026.
  • Bitdeer.AI, Bitdeer’s neo cloud business, reached US$8 million AI cloud ARR in September from providing GPU cloud services, with significant growth expected in the remaining three months of 2025. Cloud services has 584 GPUs as of September 2025, of which 501 GPUs are under subscribed, with a utilization rate of approximately 86%. The un-utilized GPUs are B200 GPUs, which were newly installed at the end of September, and are being tested by customers. Bitdeer anticipates full deployment of 1,160 GPUs by year-end.
  • Bitdeer is concurrently securing procurement agreements for NVIDIA's next-generation GB300 and B300 systems.
• Infrastructure:
  • Tydal, Norway (Hydro): All 175 MW is energized.
  • Jigmeling, Bhutan: All 500 MW is energized.
  • Niles, Ohio: Officially launched 300 MW grid-interconnected site in Niles, Ohio with a target energization date of Q1 2029.
    • Includes 41.8 acres of owned land and an interconnection agreement with FirstEnergy.
    • Located approximately 1 hour away from existing Massillon Ohio site and 2 hours away from Clarington Ohio site.
  • Total global power pipeline: Increased to 3 GW.
    
    

Management Commentary

"In September, we allowed our LOI with our development partner to expire,” said Matt Kong, Chief Business Officer at Bitdeer. “While we remain free to collaborate with this partner in the future, we have chosen to significantly expand our direct role in the HPC/AI data center market. Our expanded initiatives include negotiating directly with potential tenants, building relationships with EPCs specializing in data centers, developing proprietary AI data centers and hiring in-house experts across multiple AI data center disciplines. In parallel, we are accelerating the development of additional sites for HPC/AI data centers at our Clarington, Tydal, and Wenatchee sites. This push is driven by a marked increase in inbound interest in our power assets, which has become a strong catalyst for expanding our efforts.”

Mr. Kong continued, “Our ASICs and self-mining operational team continued to execute. In September, our first SEAL04 chip tape out was completed and initial testing demonstrates significant efficiency improvements compared to existing chips. Further, we successfully launched our SEALMINER A3 series with our Pro versions boasting a power efficiency of 12.5 J/TH. Mass production began in September and initial shipments are expected in October. In addition, our self-mining hashrate grew to 35 EH/s and remain on track to achieve 40 EH/s by end of October. Over the coming quarters, we will continue expanding our SEALMINER fleet into our near-term global power capacity, putting us on track to become one of the largest vertically integrated miners in the world.”

Production and Operations Summary

Infrastructure Construction Update

Rockdale, Texas – 100 MW Hydro-cooling conversion has been fully energized.

Tydal, Norway – 175 MW site’s construction work has been completed.

• Energization in accordance with the phase of delivery of mining rigs.
  
  

Massillon, Ohio – 221 MW site is under construction and the full energization timeline expected in Q1 2026:

• 21 MW is expected to be energized by the end of October 2025.
• The remaining 200 MW is expected to be energized in phases by the end of Q1 2026.
  
  

Clarington, Ohio – 570 MW under contract with local utility and will be available by end of Q3 2026. Power and data center infrastructure to be completed in Q2 2027.

Jigmeling, Bhutan – 500 MW site’s construction work has been completed.

• Energization in accordance with the phase of delivery of mining rigs.
  
  

Fox Creek, Alberta – 101 MW site acquired in Alberta, is fully licensed and permitted to construct an on-site natural gas power plant. The project is expected to be energized by the end of Q4 2026.

Oromia Region, Ethiopia – SPA and a turnkey agreement signed for the acquisition and construction of a 50 MW Bitcoin mining project in Ethiopia. The project is expected to be energized in Q4 2025.

Niles, Ohio – 300 MW grid-interconnected development site with a target energization date of Q1 2029 set by FirstEnergy.

• Includes 41.8 acres of owned land and an interconnection agreement with FirstEnergy.
• Former Niles Generating Station that was demolished in 2013.
• Located approximately 1 hour away from existing Massillon Ohio site and 2 hours away from Clarington Ohio site.
  
  

Upcoming Conferences and Events

• November 10 – 12, 2025: Cantor Crypto, AI/Energy Infrastructure Conference in Miami
• December 4, 2025: B. Riley Securities Convergence Conference in New York
• December 16, 2025: Northland Growth Virtual Conference 2025
• January 13 – 16, 2026: 28th Annual Needham Growth Conference in New York
  
  

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for Bitcoin mining. Bitdeer is committed to providing comprehensive Bitcoin mining solutions for its customers. Bitdeer handles complex processes involved in computing such as equipment procurement, transport logistics, data center design and construction, equipment management, and daily operations. Bitdeer also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed data centers in the United States, Norway, and Bhutan. To learn more, visit https://ir.bitdeer.com/ or follow Bitdeer on X @ BitdeerOfficial and LinkedIn @ Bitdeer Group .

Investors and others should note that Bitdeer may announce material information using its website and/or on its accounts on social media platforms, including X, formerly known as Twitter, Facebook, and LinkedIn. Therefore, Bitdeer encourages investors and others to review the information it posts on the social media and other communication channels listed on its website.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Bitdeer’s annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in Bitdeer’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof. Bitdeer specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

For investor and media inquiries, please contact:

Investor Relations
Orange Group
Yujia Zhai
[email protected]

Media
Elev8 New Media
Jessica Starman, MBA
[email protected]

Public Relations
BlocksBridge Consulting
Nishant Sharma
[email protected]

Serve’s third-generation autonomous robot was recognized in the Robotics and Automation category
This annual list honors groundbreaking advancements redefining the way we work and live

SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Serve Robotics Inc. (Nasdaq: SERV), a leading autonomous sidewalk delivery company, has been honored in Fast Company's " Next Big Things in Tech " list, securing the top spot in the Robotics and Automation category. This accolade underscores Serve's impact on last-mile logistics through its innovative, AI-powered delivery solutions.

Serve’s recognition spotlights its third-generation autonomous sidewalk delivery robot, designed to deliver faster, farther and safer than previous models. The third-generation robot operates nearly twice as fast, travels double the distance, runs six additional hours per day and carries larger cargo loads. Enhanced safety includes fail-safe mechanical brakes, autonomous collision avoidance and an emergency braking system that stops 40% faster.

Since commencing production in October 2024, Serve has deployed 1,000 Gen3 robots across major U.S. cities, including Los Angeles, Chicago, Dallas, Atlanta and Miami. The company is on track to reach its goal of 2,000 robots by the end of 2025.

Serve's growth is further propelled by strategic partnerships with leading delivery platforms. In October 2025, Serve announced a collaboration with DoorDash to integrate its autonomous delivery robots into DoorDash’s food delivery ecosystem, beginning in Los Angeles. This is in addition to its years-long partnership with Uber Eats and aims to expand Serve's reach and increase order volumes for its robot fleet, optimizing robot utilization and boosting revenue.

"Receiving this prestigious award from Fast Company is a testament to the dedication and ingenuity of our team," said Dr. Ali Kashani, CEO and co-founder of Serve Robotics. "Developing our third-generation robot required years of innovation and collaboration. This recognition validates our engineers, designers and operations teams for making autonomous delivery safer, more efficient and sustainable."

For more information or to view the complete list of honorees, visit here .
To learn more about Serve Robotics, visit www.serverobotics.com .

About Serve Robotics
Serve Robotics develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical. Spun off from Uber in 2021 as an independent company, Serve has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven. Serve has scalable multi-year contracts, including a signed agreement to deploy up to 2,000 delivery robots across multiple U.S. markets.

For further information about Serve Robotics (Nasdaq:SERV), please visit www.serverobotics.com or follow us on social media via X (Twitter) , Instagram , or LinkedIn @serverobotics.

Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Serve intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act. These forward-looking statements can be about future events, including statements regarding Serve's intentions, objectives, plans, expectations, assumptions and beliefs about future events, including Serve's expectations with respect to the financial and operating performance of its business, its capital position, and future growth. The words "anticipate", "believe", "expect", "project", "predict", "will", "forecast", "estimate", "likely", "intend", "outlook", "should", "could", "may", "target", "plan", “on track” and other similar expressions can generally be used to identify forward-looking statements. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Serve's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the United States Securities and Exchange Commission (the "SEC") and in its subsequent filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Serve undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts

Media
Aduke Thelwell, Head of Communications & Investor Relations
Serve Robotics
[email protected]

Investor Relations
[email protected]

PHILADELPHIA, PA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BTC Development Corp. (NASDAQ:BDCIU) (the “Company”) announced today that, commencing October 16, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “BDCI” and “BDCIW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “BDCIU.”

The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution. The Company’s primary focus, however, will be to identify companies in industries that complement its management team’s background, and to capitalize on the ability of its management team to identify and acquire a business, focusing on companies that provide opportunities for attractive risk-adjusted returns in the bitcoin ecosystem and/or that the Company believes have the potential to integrate bitcoin into their capital structures, balance sheets and/or operations. The management team is led by Bracebridge H. Young, Jr., its President and Chief Executive Officer, Betsy Z. Cohen, its Chairman of the Board of Directors, and Jonathan Kirkwood, its Vice-Chairman of the Board of Directors.

This press release contains statements that constitute “forward-looking statements.” When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

Contact Information:

BTC Development Corp.
[email protected]

INDIANA, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- First Commonwealth Financial Corporation (NYSE: FCF) announced today that it will host a conference call on Wednesday, October 29, 2025 at 2:00 p.m. Eastern Time to discuss financial results for the quarter ended September 30, 2025. The call will be hosted by T. Michael Price, President and Chief Executive Officer. He will be joined by James R. Reske, Executive Vice President and Chief Financial Officer, Jane Grebenc, Executive Vice President and Chief Revenue Officer and Brian J. Sohocki, Executive Vice President and Chief Credit Officer. First Commonwealth will issue a press release reporting its third quarter 2025 financial results after the market closes on Tuesday, October 28, 2025.

Conference Call Information

To listen to the conference call, either dial the phone number above or go to First Commonwealth's Investor Relations webpage at www.fcbanking.com/investorrelations , click on the "Third Quarter 2025 Earnings Conference Call" link and follow the instructions.  After the live presentation, the webcast will be archived on this website for at least 30 days.   In addition, a replay of the call will be available approximately one hour after the conclusion of the call by dialing the replay number and entering the access code listed above. There is no charge to access this event.

To Ask Questions

Participants can e-mail their questions to [email protected] . Questions submitted via e-mail will be accepted beginning at 9:00 a.m. Eastern Time on Wednesday, October 29, 2025, until the conclusion of the presentation.

Third Quarter 2025 Earnings Release

The First Commonwealth Financial Corporation Third Quarter 2025 earnings press release can be accessed after it is published on Tuesday, October 28, 2025 at w ww.fcbanking.com/investorrelations . Click on "News," which can be found under the “News & Market Data” section.

About First Commonwealth Financial Corporation

First Commonwealth Financial Corporation (NYSE: FCF), headquartered in Indiana, Pennsylvania, is a financial services company with 127 community banking offices in 30 counties throughout western and central Pennsylvania and throughout Ohio, as well as commercial lending operations in Pittsburgh and Harrisburg, Pennsylvania, and Canton, Cleveland, Columbus and Cincinnati, Ohio. The company also operates mortgage offices in Wexford, Pennsylvania, as well as Hudson and Lewis Center, Ohio.  First Commonwealth provides a full range of commercial banking, consumer banking, mortgage, equipment finance, wealth management and insurance products and services through its subsidiaries First Commonwealth Bank and First Commonwealth Insurance Agency.  For more information about First Commonwealth or to open an account today, please visit www.fcbanking.com .

Media Relations
Ron Wahl
Communications and Media Relations
Phone: 724-463-6806
E-mail: [email protected]

Investor Relations
Ryan M. Thomas
FP&A and Investor Relations
Phone: 724-463-1690
E-mail: [email protected]

Adds a new $247 million warehouse facility with Citizens Financial Group, Inc. and Community Investment Management

Extends the term of an existing warehouse facility with Goldman Sachs and Jefferies by 12 months

Increases weighted average remaining term of combined warehouse facilities from 17 months to 25 months

Proactively paid down $17.5 million of higher cost corporate debt in October, resulting in $50 million of total corporate debt paid down since October 2024

SAN CARLOS, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven financial services company, today announced several enhancements to its debt capital structure:

• The closing of a new $247 million, three-year revolving term committed warehouse facility with Citizens Financial Group, Inc., as senior lender and Community Investment Management, as mezzanine lender.
  
  
• A 12-month extension of an existing warehouse facility with Goldman Sachs as senior lender and Jefferies as mezzanine lender.
  
  
• Both warehouse facilities were priced more favorably than existing warehouse facilities and reduced overall warehouse financing costs. The structure of the other existing warehouse facilities remains unchanged.
  
  
• An increase in total committed warehouse capacity from $954 million to $1.14 billion, and an increase in the weighted average remaining term for combined warehouse facilities from 17 months to 25 months.
  
  
• The repayment of $17.5 million of higher cost corporate debt since the end of the third quarter, resulting in a total corporate debt pay-down of $50 million since the facility’s inception in October 2024.
  

“Reducing total warehouse financing costs while increasing committed warehouse capacity helps ensure Oportun is well placed to continue delivering for our investors and members,” said Paul Appleton, Interim Chief Financial Officer at Oportun. “The support from our existing lender group and the addition of two new capital partners combined with Oportun’s continued focus on paying down higher cost corporate debt strengthens our balance sheet and helps the company provide affordable credit to more qualified borrowers.”

After the end of the third quarter, Oportun proactively repaid the remaining $7.5 million of the $27.5 million in mandatory corporate loan payments due by January 2026, along with an additional $10 million eligible for early repayment without penalties.

Oportun has now reduced the initial October 2024 $235 million balance on its higher cost corporate financing facility to $185 million.

For more information visit oportun.com .

About Oportun
Oportun (Nasdaq: OPRT) is a mission-driven financial services company that puts its members' financial goals within reach. With intelligent borrowing, savings, and budgeting capabilities, Oportun empowers members with the confidence to build a better financial future. Since inception, Oportun has provided more than $20.8 billion in responsible and affordable credit, saved its members more than $2.5 billion in interest and fees, and helped its members set aside an average of more than $1,800 annually. For more information, visit Oportun.com.

About Citizens Financial Group, Inc.
Citizens Financial Group, Inc. is one of the nation’s oldest and largest financial institutions, with $218.3 billion in assets as of June 30, 2025. Headquartered in Providence, Rhode Island, Citizens offers a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. Citizens helps its customers reach their potential by listening to them and by understanding their needs in order to offer tailored advice, ideas and solutions. In Consumer Banking, Citizens provides an integrated experience that includes mobile and online banking, a full-service customer contact center and the convenience of approximately 3,000 ATMs and approximately 1,000 branches in 14 states and the District of Columbia. Consumer Banking products and services include a full range of banking, lending, savings, wealth management and small business offerings. In Commercial Banking, Citizens offers a broad complement of financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, interest rate and commodity risk management solutions, as well as loan syndication, corporate finance, merger and acquisition, and debt and equity capital markets capabilities. More information is available at www.citizensbank.com or visit us on X, LinkedIn or Facebook.

About Community Investment Management
Community Investment Management (CIM) is a global institutional investment manager providing strategic debt capital to scale responsible innovation in lending. As part of its investment mandate, CIM partners with fintechs to address credit gaps in the US and emerging markets. For more information, visit https://cim-llc.com.

About Goldman Sachs
Goldman Sachs is a leading global financial institution that delivers a broad range of financial services to a large and diversified client base that includes corporations, financial institutions, governments and individuals. Founded in 1869, the firm is headquartered in New York and maintains offices in all major financial centers around the world.

About Jefferies
Jefferies (NYSE: JEF) is a leading global, full-service investment banking and capital markets firm that provides advisory, sales and trading, research and wealth and asset management services. With more than 47 offices in 21 countries around the world, we offer insights and expertise to investors, companies and governments.

Investor Contact
Dorian Hare
(650) 590-4323
[email protected]

Media Contact
Michael Azzano
Cosmo PR for Oportun
(415) 596-1978
[email protected]

Hangzhou, China, Oct. 14, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that the Company received a determination letter, dated October 9, 2025 (the “Letter”), from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company of Nasdaq’s determination to delist the Company’s Class A ordinary shares from The Nasdaq Capital Market, because the Company’s Class A ordinary shares had a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025, which triggered a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii).

Pursuant to the Letter, unless the Company requests an appeal, trading of the Company’s Class A ordinary shares will be suspended at the opening of business on October 20, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq.

The Company has the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal this determination, with such request due by October 16, 2025. A request for a hearing will stay the suspension of the Company’s securities pending the Panel’s decision. The Company plans to appeal the determination to the Panel on or before October 16, 2025.

The Company will consider all available options to regain compliance with the Nasdaq Listing Rules for continued listing on Nasdaq, including, if appropriate, implementing a reverse share split.

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate .

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

For more information, please contact:

WORK Medical Technology Group LTD
Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

DELRAY BEACH, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

Fiscal 2025 Financial Highlights

• Net sales of $227.0 million for fiscal 2025, below the preliminary estimated range of $231.6 million to $233.6 million, primarily due to the previously announced restatement of promotional sales reimbursements from revenues to cost of sales, which had no impact on net income
• Net loss of $6.3 million, more than the previously announced preliminary estimated range of $4.5 million to $5.0 million, primarily due to the previously announced $1.2 million non-cash impairment charge for intangible assets
• Cash of $54.7 million as of March 31, 2025, and no debt
  

“We greatly appreciate the patience of our shareholders over the past several months,” said Board Chair and Interim CEO Leslie C. G. Campbell. “With our Form 10-K for fiscal 2025 now filed and actions taken to enhance our internal processes, we can now fully dedicate our efforts to operational execution and building a platform for long-term value creation. Most importantly we will continue to deliver to our customers the care they trust, which has been our legacy as a pioneer in the digital pharmacy industry for nearly 30 years. We now plan to file, as soon as practicable, our Quarterly Report on Form 10-Q for the first quarter ended June 30, 2025, followed by our earnings results and corresponding filings for the second quarter ended September 30, 2025, and thereby resume the normal quarterly reporting schedule. While we are unable at this time to determine exact dates for our Q1 and Q2 filings with the SEC or the related earnings announcements, we expect to resume our normal cadence of quarterly earnings calls promptly once our SEC filings are current.”

About PetMed Express, Inc.
Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Company’s efforts to leverage its brand and legacy as a pioneer in the digital pet pharmacy industry for nearly 30 years, enhance its operational execution, and build a platform for long-term value creation, as well as statements regarding the anticipated timing for the filing of the Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 and the related earnings announcements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events, which are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors, including but not limited to, the results of the now completed investigation by the Audit Committee of the Company’s Board of Directors, the risk that the completion of the filing of the Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 may take longer than expected, and other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investor Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
[email protected]

ANDOVER, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Mercury Systems Inc. (NASDAQ: MRCY, www.mrcy.com ), a global technology company that delivers mission-critical processing to the edge, will release its first quarter fiscal year 2026 financial results after the market close on Tuesday, November 4, 2025.

Management will host a conference call and simultaneous webcast at 5:00 p.m. ET on the same day to discuss Mercury's quarterly financial results, business highlights, and outlook. In addition, Company representatives may answer questions concerning business and financial developments and trends, the Company's view on earnings forecasts, and other business and financial matters affecting the Company, the responses to which may contain information that has not been previously disclosed.

To attend the conference call or webcast, participants should register online at ir.mrcy.com/events-presentations . Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the webcast will be available two hours after the call and archived on the same web page for six months.

Mercury Systems – Innovation that matters®
Mercury Systems is a global technology company that delivers mission-critical processing to the edge, making advanced technologies profoundly more accessible for today’s most challenging aerospace and defense missions. The Mercury Processing Platform allows customers to tap into innovative capabilities from silicon to system scale, turning data into decisions on timelines that matter. Mercury’s products and solutions are deployed in more than 300 programs and across 35 countries, enabling a broad range of applications in mission computing, sensor processing, command and control, and communications. Mercury is headquartered in Andover, Massachusetts, and has more than 20 locations worldwide. To learn more, visit mrcy.com. (Nasdaq: MRCY)

CONTACT
Tyler Hojo, CFA
Vice President, Investor Relations
[email protected]

MILWAUKEE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Artisan Partners Asset Management Inc. (NYSE: APAM) will report its third quarter 2025 financial results and information relating to its quarterly dividend on October 28, 2025 at approximately 4:30 p.m. (Eastern Time). Artisan Partners Asset Management’s earnings release and supplemental materials will be available on the investor relations section of artisanpartners.com at that time. Chief Executive Officer and President Jason Gottlieb and Chief Financial Officer C.J. Daley will host a conference call on October 29, 2025 at 1:00 p.m. (Eastern Time) to discuss the results.

A live webcast of the conference call will be available via the investor relations section of artisanpartners.com. Those interested in participating in the conference call should dial:

An audio replay of the conference call will be available one hour after the end of the conference until November 5, 2025 at 9:00 a.m. (Eastern Time) by dialing the following:

An audio replay will also be available via the investor relations section of artisanpartners.com within 24 hours after the end of the conference.

About Artisan Partners

Artisan Partners is a global multi-asset investment platform providing a broad range of high value-added investment strategies in growing asset classes to sophisticated clients around the world. Since 1994, the firm has been committed to attracting experienced, disciplined investment professionals to manage client assets. Artisan Partners’ autonomous investment teams oversee a diverse range of investment strategies across multiple asset classes. Strategies are offered through various investment vehicles to accommodate a broad range of client mandates.

Artisan Partners Asset Management Inc.

Investor Relations Inquiries
866.632.1770
[email protected]

WAIKOLOA, Hawaii, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Hawaii Water Service (Hawaii Water), a subsidiary of California Water Service Group (NYSE: CWT), has received approval from the Hawaii Public Utilities Commission (HPUC) to increase annual revenue by $4.7 million across the five systems that make up its Waikoloa service area, and to adjust water and wastewater rates accordingly. This increase in annual revenue is necessary to account for investments made to maintain and strengthen the Waikoloa Resort and Village water and wastewater systems, inflation, and operating cost increases.

Over recent years, Hawaii Water has completed numerous capital investment projects to help provide safe, reliable service, including:

• Almost $17 million for drinking water well and sewer pump station improvements, along with backup power generators, to improve supply and system reliability—even during power interruptions.
• More than $8 million in transmission and distribution pipelines to reduce leaks and increase reliability.
• Almost $8 million for water and wastewater treatment plant improvements to continue meeting water quality and environmental standards, and increase treatment capacity.
  

In total, Hawaii Water has invested approximately $33 million in its Waikoloa systems since its last rate adjustment in 2019.

“We take our responsibility to provide safe, reliable drinking water and wastewater service to our Waikoloa Resort and Village customers seriously, while working to protect the environment,” said Marty Kropelnicki, Group Chairman and CEO. “Making proactive infrastructure upgrades and maintenance, along with operating efficiently, are important to fulfilling that duty and keeping costs affordable in the long term. This enables us to provide quality, service, and value to our customers.”

In the decision, the HPUC also approved a fixed charge for non-residential water system customers for conservation-related activities. New rates are effective as of October 9, 2025.

About California Water Service Group
California Water Service Group is the parent company of regulated utilities California Water Service, Hawaii Water Service, New Mexico Water Service, and Washington Water Service, as well as regulated operating utilities held by Texas Water Service through a 96-percent-owned joint venture. Together, these companies provide regulated and non-regulated water and wastewater service to more than 2.1 million people in California, Hawaii, New Mexico, Washington, and Texas. California Water Service Group’s common stock trades on the New York Stock Exchange under the symbol “CWT.” Additional information is available online at www.calwatergroup.com .

Media Contact
Yvonne Kingman
[email protected]
310-257-1434

RALEIGH, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE:MLM) (“Martin Marietta” or the “Company”) will host its third-quarter 2025 earnings conference call on Tuesday, November 4, 2025, at 10:00 a.m. Eastern Time. The Company will release results for the quarter ended September 30, 2025, that morning before the market opens.

A live, listen-only webcast and supplemental information will be accessible on the Investors section of the Company’s website at www.martinmarietta.com . The conference call may also be accessed by dialing +1 (646) 307-1963 and using conference ID 6474847. Please dial in at least 15 minutes in advance to ensure a timely connection. An on-demand replay will be available on the Company’s website approximately two hours following the conclusion of the live broadcast and will be available for one year.

Martin Marietta, a member of the S&P 500 Index, is an American-based company and a leading supplier of building materials, including aggregates, cement, ready mixed concrete and asphalt. Through a network of operations spanning 28 states, Canada and The Bahamas, dedicated Martin Marietta teams supply the resources necessary for building the solid foundations on which our communities thrive. Martin Marietta’s Specialties business produces high-purity magnesia and dolomitic lime products used worldwide in environmental, industrial, agricultural and specialty applications. For more information, visit www.martinmarietta.com or www.magnesiaspecialties.com .

Investor Contact:
Jacklyn Rooker
Vice President, Investor Relations
(919) 510-4736
[email protected]

MLM-E .

WASHINGTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it is commencing an underwritten public offering of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cantor and Lucid Capital Markets are acting as joint book-running managers for the offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (“SEC”) on October 14, 2025, which was immediately effective upon filing.

A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor New York, New York 10022; Email: [email protected] or Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About ASP Isotopes Inc.

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com .

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements include, but are not limited to, statements regarding the Company’s anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and other statements that are not historical facts. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including: the failure to obtain necessary regulatory and shareholder approvals for the proposed acquisition of Renergen; disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; significant transaction costs and unknown liabilities related to the proposed acquisition of Renergen; litigation or regulatory actions related to the proposed acquisition of Renergen; the outcomes of various strategies and projects undertaken by the Company; the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties; our ability to complete the proposed the construction and commissioning of our enrichment plant(s) or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. “Risk Factors” of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company’s subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.

Contacts

Jason Assad– Investor relations
Email: [email protected]
Telephone: 561-709-3043

SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sonder Holdings Inc. (Nasdaq: SOND) (“Sonder” or the “Company”), a leading global brand of premium, design-forward apartments and intimate boutique hotels serving the modern traveler, today announced its financial results for the second quarter 2025, ended June 30, 2025, and filed the related Quarterly Report on Form 10-Q (the “Q2 2025 Form 10-Q”), which can be found on the Company’s website at investors.sonder.com.

Second Quarter 2025 Financial Highlights ¹

• RevPAR was $184, a 13% increase year-over-year
• Occupancy Rate was 86%, a six percentage point increase year-over-year
• Bookable Nights were 798,000, a 21% decrease year-over-year, driven by the Company’s Portfolio Optimization Program, as described in the Q2 2025 Form 10-Q
• Revenue was $147.1 million, a 11% decrease year-over-year
• Net Loss was $44.5 million, a 236% decrease year-over-year
• Adjusted EBITDA ³ was $(2.6) million, a 83% increase year-over-year
• Adjusted EBITDAR ³ was $58.6 million, a 1% increase year-over-year
• Cash Used In Operating Activities was $19.6 million, a 40% improvement year-over-year
• Adjusted Free Cash Flow ³ was $(17.5) million, a 29% decrease year-over-year
• Total Cash, Cash Equivalents and Restricted Cash was $71.0 million, which included $43.8 million of restricted cash as of June 30, 2025
• Live Units were approximately 8,300 as of June 30, 2025
• Total Portfolio was approximately 8,990 as of June 30, 2025
  
  

Second Quarter 2025 Year-to-Date Financial Highlights ²

• RevPAR was $161, a 13% increase year-over-year
• Occupancy Rate was 84%, a seven percentage point increase year-over-year
• Bookable Nights were 1,656,000, a 21% decrease year-over-year, driven by the Company’s Portfolio Optimization Program, as described in the Q2 2025 Form 10-Q
• Revenue was $265.9 million, a 11% decrease year-over-year
• Net Loss was $101.0 million, a 469% decrease year-over-year
• Adjusted EBITDA ³ was $(59.3) million, a (20.3)% increase year-over-year
• Adjusted EBITDAR ³ was $79.8 million, a 5% decrease year-over-year
• Cash Used In Operating Activities was $24.0 million, an 67% improvement year-over-year
• Adjusted Free Cash Flow ³ was $(24.4) million, a 54.2% decrease year-over-year
  
  

Long-Term Strategic Licensing Agreement with Marriott International

Sonder entered into a long-term strategic licensing agreement with Marriott International, Inc. (“Marriott”) in August 2024 and completed the full Marriott integration in the second quarter of 2025. As of June 2025, all Sonder properties are available for booking on Marriott’s digital channels and platform, including Marriott.com and the Marriott Bonvoy® mobile app under the new “Sonder by Marriott Bonvoy” collection. Sonder’s properties also participate in the Marriott Bonvoy® travel platform.

About Sonder
Sonder (NASDAQ: SOND) is a leading global brand of premium, design-forward apartments and intimate boutique hotels serving the modern traveler. Launched in 2014, Sonder offers inspiring, thoughtfully designed accommodations and innovative, tech-enabled service combined into one seamless experience. Sonder properties are found in prime locations in 37 cities, spanning nine countries, and three continents.

To learn more, visit http://www.sonder.com or follow Sonder on Instagram , LinkedIn or X .

Download the Sonder app on Apple or Google Play .

Media:
[email protected]

Investor:
[email protected]

_{¹ $ figures represent metrics for the three months ended June 30, 2025, except where otherwise noted. % figures represent year-over-year growth for the three months ended June 30, 2025 compared to the three months ended June 30, 2024.
² $ figures represent metrics for the six months ended June 30, 2025, except where otherwise noted. % figures represent year-over-year growth for the six months ended June 30, 2025 compared to the six months ended June 30, 2024.
³ Adjusted EBITDA, Adjusted EBITDAR, and Adjusted Free Cash Flow are non-GAAP financial measures. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.}

_{(1) See Non-GAAP Financial Measures section for definitions of the Company’s Non-GAAP financial measures.}

Definitions

RevPAR
Revenue Per Available Room (“RevPAR”) represents the average revenue earned per available night and can be calculated either by dividing revenue by Bookable Nights, or by multiplying Average Daily Rate by Occupancy Rate. Average Daily Rate represents the average revenue earned per night occupied and is calculated as Revenue divided by Occupied Nights. Occupancy Rate is calculated as Occupied Nights divided by Bookable Nights. Bookable Nights represent the total number of nights available for stays across all Live Units. This excludes nights lost to full building closures of greater than 30 nights. Occupied Nights represent the total number of nights occupied across all Live Units.

Live Units & Total Portfolio
Total Portfolio consists of Live Units and Contracted Units. Live Units are defined as units which are available for guests to book. Contracted Units are units for which Sonder has signed real estate contracts, but are not yet available for guests to book.

Non-GAAP Financial Measures

Adjusted EBITDA
Adjusted EBITDA is defined as net income (loss) as adjusted to eliminate the impact of net interest expense, provision (benefit) for income taxes, depreciation and amortization expense, and certain other items as indicated. The exclusion of these items and other similar items in our non-GAAP presentation should not be interpreted as implying that these items are non-recurring, infrequent or unusual. The Company believes Adjusted EBITDA is meaningful to investors as it is the primary operating performance measure that the Company focuses on internally to evaluate its core operating performance. Adjusted EBITDA provides a consistent basis for comparison across reporting periods by excluding interest, taxes, depreciation and amortization, and certain non-recurring or non-operational items, such as stock-based compensation expense, lease adjustment gains, net, cash received for lease terminations, integration costs, loss on preferred stock issuance, gain on foreign exchange, restructuring and other related charges and non-recurring professional fees related to discrete projects such as fees associated with the integration in connection with the strategic licensing agreement with Marriott and restatement activities. It serves as a key measure for the Company to align its financial performance with its internal financial planning and analysis.

Adjusted EBITDAR
Adjusted EBITDAR is defined as Adjusted EBITDA adjusted for operating lease related rent charges. The Company believes Adjusted EBITDAR is meaningful to investors as it is an operating performance measure that further enables the Company to assess its operating performance independent of operating leases, offering insights into its cash flow and performance.

Adjusted Free Cash Flow
Adjusted Free Cash Flow (“Adjusted FCF”) is defined as cash used in operating activities plus cash provided by (used in) investing activities, excluding the impact of lease terminations, restructuring, non-recurring professional fee charges and integration costs related to non-operational activities. The most directly comparable GAAP financial measures are cash used in operating activities when combined with cash provided by (used in) investing activities. The Company believes Adjusted FCF is meaningful to investors as it is the primary liquidity measure that the Company focuses on internally to evaluate its progress towards the objectives outlined in its Cash Flow Positive Plan. The Company believes that achieving its goals around this measure will put it on a path to financial sustainability and will help fund its future growth. In addition, Adjusted FCF may not provide a complete understanding of the Company’s cash flow as a whole. As such, this measure should be reviewed in conjunction with the Company’s GAAP cash flow.

Presentation of these measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based upon current expectations or beliefs, as well as assumptions about future events. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “could,” "estimate," “expect,” “intend,” “may,” “plan,” "potentially," or “will” or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements relating to the Company’s financial performance, key performance metrics, operational and strategic initiatives, the Company’s long-term strategic licensing agreement with Marriott, and information concerning possible or assumed future financial or operating results and measures. These forward-looking statements are not guarantees of future performance, conditions or results. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including the risks and uncertainties described in the Company’s reports filed with the Securities and Exchange Commission, and under the heading “Risk Factors” in its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at www.sec.gov and are incorporated by reference herein. The forward-looking statements contained herein are only as of the date of this press release. Except as required by law, the Company does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.

SEATTLE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that Banzai Founder and CEO Joe Davy, and CFO Dean Ditto will attend the LD Micro Main Event XIX Conference taking place October 20-21, 2025, at the Hotel Del Coronado in San Diego. Mr. Davy will also host an in-person presentation and webcast on Monday, October 20, 2025, at 10:00 AM PT/1:00 PM ET in Track 2.

LD Micro Main Event XIX
Date: October 20-21, 2025
Location: Hotel Del Coronado, San Diego, CA
Format: In-person one-on-one meetings, In-person presentation
Attendees: Founder and CEO Joe Davy, CFO Dean Ditto
Presentation: Monday, October 20, 2025, at 10:00 AM PT/1:00 PM ET in Track 2
Webcast Registration: https://ldmicrocasts.com/#register
Conference Website: Click here

To schedule a one-on-one investor meeting with Banzai management, please contact your LD Micro conference representative or email your request to at [email protected] or call Chris Tyson at (949) 491-8235.

About Banzai

Banzai is a marketing technology company that provides AI-enabled marketing and sales solutions for businesses of all sizes. On a mission to help their customers grow, Banzai enables companies of all sizes to target, engage, and measure both new and existing customers more effectively. Banzai has over 140,000 customers including RBC, Dell Technologies, New York Life, Thermo Fisher Scientific, Thinkific, and ActiveCampaign. Learn more at www.banzai.io . For investors, please visit https://ir.banzai.io .

Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
[email protected]
www.mzgroup.us

Media
Nancy Norton
Chief Legal Officer, Banzai
[email protected]

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 –

– New preclinical data demonstrates that vorolanib, the active drug in DURAVYU, inhibits both VEGF-mediated vascular permeability and IL-6 mediated inflammation, key contributors to wet AMD and DME –

– IL-6 finding supports the compelling efficacy data observed in the Phase 2 VERONA DME trial and underscores DURAVYU as a potential 6-month treatment –

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced details for its pivotal Phase 3 program evaluating DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME) with first patient dosing anticipated in first quarter of 2026. The Company also shared new preclinical data that demonstrates vorolanib, the active drug in DURAVYU, inhibits interleukin-6 (IL-6) mediated inflammation through inhibition of all Janus Kinase (JAK) receptors, in particular JAK-1, in addition to known blockage of vascular endothelial growth factor (VEGF) mediated vascular permeability. This finding reinforces the early and sustained improvements observed through six months in the Phase 2 VERONA clinical trial and positions DURAVYU as a potential multi-mechanism of action (MOA) treatment.

“Following a positive end of Phase 2 meeting with the FDA, we are pleased to announce the initiation of our Phase 3 pivotal trials for DME, following an established non-inferiority approval pathway for this important indication,” said Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer at EyePoint. “Despite available anti-VEGF therapies, many DME patients continue to lose vision, underscoring the need for a sustained delivery option that also addresses inflammation. Our new preclinical data demonstrates that in addition to the known blockage of VEGF, DURAVYU also blocks IL-6 mediated inflammation via inhibition of the JAK receptors, particularly JAK-1, making DURAVYU a potential multi-MOA option for physicians and patients. Our Phase 3 pivotal program preparations are well underway, and we anticipate dosing our first patient in the first quarter of 2026 positioning DURAVYU to be the first TKI to market in two significant indications.”

DURAVYU Phase 3 DME Clinical Program Overview

• U.S. Food and Drug Administration (FDA) alignment on approval pathway in DME consisting of two identical non-inferiority trials (“COMO” and “CAPRI”). The trials will include redosing of DURAVYU every six months.
• Each trial will enroll approximately 240 patients, including both previously treated and treatment naïve patients, who will be randomly assigned to either a DURAVYU 2.7mg arm or an on-label 2mg aflibercept control arm. Randomization occurs on Day 1.
• The primary endpoint is the change from baseline in best corrected visual acuity (BCVA) to weeks 52 and 56, blended, compared to on-label 2mg aflibercept.
  
  

Data Supporting DURAVYU™ for the Treatment of DME

New data demonstrates that DURAVYU has the potential to be a multi-MOA treatment, inhibiting both VEGF via inhibition of all VEGFRs and IL-6 signaling via JAK receptor blockage. IL-6 is a pro-inflammatory cytokine that has been observed at significantly higher levels in patients with DME and wet AMD compared to healthy individuals. IL-6 signaling occurs via activation of the JAK kinases, particularly JAK-1, leading to vascular leakage and inflammation that together compound damage to the blood-retinal barrier in DME.

There remains a clear need for treatment options that address both the VEGF-mediated vascular leakage and inflammation drivers of this disease, as well as treatment burden. Up to two-thirds of patients still have active DME after anti-VEGF loading, underscoring the multifactorial nature of the disease and suboptimal efficacy associated with a single-mechanism approach.

Vorolanib is a potent and selective tyrosine kinase inhibitor (TKI) that inhibits all VEGF and JAK receptors, particularly JAK-1, with new in vitro data showing a reduction in IL-6 activity of more than 50% potentially bringing a synergistic anti-inflammatory effect in addition to established VEGF inhibition. Furthermore, DURAVYU features sustained drug delivery providing consistent daily dosing with receptor inhibition for at least six months after a single injection. The positive efficacy results from the Phase 2 VERONA trial, where a single DURAVYU 2.7mg dose demonstrated early and meaningful improvements in vision and anatomy compared to aflibercept, further underscore the potential clinical utility in DME.

“DME remains chronically undertreated, with patients experiencing persistent disease despite receiving standard of care anti-VEGFs,” said Roger A. Goldberg, MD, MBA, Vitreoretinal Surgeon at Bay Area Retina Associates; Co-Founder, Emmetrope Ophthalmics, LLC. “We know that inflammation plays a critical role in the pathogenesis of DME, and there is an urgent need for new treatment options that address the multifactorial nature of this disease while reducing the high treatment burden associated with existing therapies. I am thrilled that DURAVYU—the only TKI in development for center involving DME—plans to advance to a registrational program. Following the promising VERONA data, in particular the early and sustained visual acuity improvements with a superior dosing interval versus aflibercept and continued favorable safety profile, the retinal community is enthusiastic to see this program move forward in DME, and for the possibility of achieving better outcomes for our patients.”

The Company will be presenting the preclinical data on JAK/IL-6 inhibition at the Eyecelerator meeting at AAO 2025.

About Diabetic Macular Edema

Diabetic macular edema (DME) is the leading cause of vision loss in people with type 1 and type 2 diabetes. DME results when damaged blood vessels leak fluid into the macula, the central portion of the retina responsible for the sharp vision needed for routine tasks such as driving or reading. DME is driven by both VEGF production and inflammation associated with interleukin-6 (IL-6) signaling. This resulting retinal swelling can cause blurred vision and may lead to severe vision loss or even blindness. DME is a common form of sight-threatening retinopathy in people with diabetes, with approximately 28 million people afflicted worldwide. As the prevalence of diabetes continues to grow, an increased number of people will be affected by diabetic eye diseases such as DME. The current standard of care for patients experiencing DME includes intravitreal injections of short-acting anti-VEGF biologics, corticosteroids, or laser photocoagulation which can become a burden on patients, caregivers, and physicians due to the longevity of the disease.

About DURAVYU™

DURAVYU™ (vorolanib intravitreal insert), is being developed as a potential sustained-delivery treatment for patients suffering from serious retinal diseases. It is designed for intravitreal dosing in a pre-loaded syringe injector to deliver a consistent therapeutic dose for at least six months. DURAVYU combines vorolanib in next-generation Durasert E™ technology: Durasert E is EyePoint’s proprietary and best-in-class bioerodible sustained release insert with a matrix designed for sustained release of drug while prevent free-floating drug particles. DURAVYU contains no PEG or PLGA.

Vorolanib is a differentiated and patent-protected tyrosine kinase inhibitor and is the most studied TKI in retinal disease, with proven ocular safety. Vorolanib targets both VEGF-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF and JAK receptors bringing a novel, multi-mechanism of action for retinal disease. Vorolanib has also demonstrated neuroprotection in an in vivo model of retinal detachment and inhibits PDGF, which may have antifibrotic benefits.

DURAVYU has efficacy data across approximately 140 wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) patients in both Phase 1 and 2 trials that demonstrate stability in vision and anatomical control with fewer injections. Data from the Phase 2 trial demonstrated an impressive treatment burden reduction of approximately 88% six months after treatment with DURAVYU, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection. Importantly, no safety signals or ocular SAEs related to DURAVYU have been observed in 190+ patients across four clinical trials, including three Phase 2 trials.

The wet AMD Phase 3 pivotal program (LUGANO and LUCIA) is evaluating every six-month re-dosing of DURAVYU allowing for a flexible label for physicians. The Phase 3 pivotal program follows a well-established regulatory approval pathway with a patient-centric non-inferiority design comparing DURAVYU to on-label standard of care to inform real-word treatment practices.

DURAVYU is also currently being evaluated for the treatment of diabetic macular edema (DME) with first patient dosing in Phase 3 trials expected in Q1 2026. The Phase 2 VERONA trial in DME met primary and secondary endpoints and demonstrated a rapid and sustained improvement in vision and anatomy, a continued favorable safety and tolerability profile with superior dosing intervals to standard of care.

About EyePoint

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU ^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Forward Looking Statements

EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding our clinical development and regulatory plans of DURAVYU; our expectations regarding timing for the completion of clinical trial enrollment and the timing of the availability and release of clinical data; our optimism that DURAVYU has the potential to improve patient outcomes; our expectations regarding clinical development of our other product candidates, our business strategies and objectives; and other statements regarding the Company’s future plans, objectives, strategies and beliefs, as identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” or other words of similar meaning or the use of future dates.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the Company’s clinical development activities, including DURAVYU; uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU; unanticipated costs and expenses; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company’s product candidates; changes in the regulatory environment; disruptions at the FDA, including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA; changes in U.S. and international trade policies; the impact of the government shutdown on our business operations; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the Company’s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. A more complete discussion of the risks and uncertainties that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, in our other filings with the Securities and Exchange Commission (SEC) and in our future reports to be filed with the SEC, which are available at www.sec.gov . Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
[email protected] / [email protected]

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
[email protected]

ATLANTA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a leading provider of global software and data in the HR technology industry, has been included in Newsweek’s World’s Most Trustworthy Companies 2025 list. This prestigious award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.

Trust is vital for companies as it fosters customer loyalty, strengthens brand reputation, boosts employee morale, and builds investor confidence. The World’s Most Trustworthy Companies 2025 list highlights those companies that have earned the highest levels of trust globally.

“We are thrilled to be recognized by Newsweek as one of the World’s Most Trustworthy Companies for 2025. This distinction is a testament to the integrity, transparency, and dedication our team brings to every customer interaction. Trust is the foundation of our business, and being acknowledged for it on a global scale reinforces our commitment to delivering reliable, secure, and innovative solutions that empower organizations worldwide,” said Scott Staples, Chief Executive Officer.

First Advantage is honored to be recognized on Newsweek’s list of the World’s Most Trustworthy Companies 2025 and proud to add this to our recent achievements including a Stevie Award in the Customer Service Success – Technology Industries category and being named a Top Solution Provider in the Marketplace Risk Excellence Program.

The World’s Most Trustworthy Companies 2025 were identified in an independent survey based on a vast sample of more than 65,000 participants in 23 industries spanning 20 countries. The participants rated companies they knew and that were headquartered in the respective country in terms of three touchpoints of trust: Investor Trust, Customer Trust, and Employee Trust. Approximately 200,000 evaluations were analyzed. For each company that received enough evaluations, a social listening analysis was conducted. This phase of the project involved a sentiment analysis of the companies on several media segments of the internet and evaluating their mentions as either positive, neutral, or negative. All stock-listed companies headquartered in one of the target countries with a revenue of over 500 million USD were considered in the study.

About First Advantage

First Advantage (NASDAQ: FA) is a leading provider of global software and data in the HR technology industry. Enabled by its proprietary technology and AI, First Advantage’s platforms, data, and APIs power comprehensive employment background screening, digital identity solutions, and verification services. With a strong emphasis on innovation, automation, and customer success, First Advantage empowers 80,000 organizations to hire smarter and onboard faster. Headquartered in Atlanta, Georgia, First Advantage serves customers in over 200 countries and territories, modernizing hiring and onboarding on a global scale. For more information, please visit our website at https://fadv.com/ .

Media Contact

Katelyn Brower
Director, PR, Social, Events
[email protected]

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) (“IREN”) today announced the closing of its offering of $1.0 billion aggregate principal amount of 0.00% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Key details of the transaction

• Oversubscribed $875 million offering, plus fully exercised $125 million greenshoe
• Net proceeds of approximately $979.0 million
• 0.00% coupon, 42.5% conversion premium
• No put option for investors in the notes (other than a customary put right in the case of certain fundamental changes)
• Capped call transactions entered into in connection with the notes, which are generally expected to provide a hedge upon conversions up to an initial cap price of $120.18 per share, which represents a 100% premium (as compared to the 42.5% conversion premium under the notes)
• Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC acted as active bookrunners
  
  

Oversubscribed

As a result of strong investor demand, the offering was oversubscribed, and the initial purchasers fully exercised their option to purchase an additional $125 million aggregate principal amount of the notes. The notes were issued pursuant to, and are governed by, an indenture, dated as of October 14, 2025, between IREN and U.S. Bank Trust Company, National Association, as trustee.

Use of proceeds

The net proceeds from the offering are approximately $979.0 million, after deducting the initial purchasers’ discounts and commissions and IREN’s estimated offering expenses.

IREN intends to use the net proceeds as follows:

• $56.7 million to fund the cost of the capped call transactions (described below)
• General corporate purposes and working capital
  
  

Capped call transactions

In connection with the pricing of the notes and the exercise by the initial purchasers of their option to purchase additional notes, IREN entered into privately negotiated capped call transactions with one of the initial purchasers or its affiliate and certain other financial institutions (the “option counterparties”). The capped call transactions cover, subject to anti-dilution adjustments, the number of ordinary shares of IREN that initially underlie the notes. The cap price of the capped call transactions is initially $120.18 per share, which represents a premium of 100% over the last reported sale price of IREN’s ordinary shares of $60.09 per share on October 8, 2025, and is subject to certain adjustments under the terms of the capped call transactions.

The capped call transactions are expected generally to reduce the potential dilution to IREN’s ordinary shares upon any conversion of the notes and/or offset any potential cash payments IREN is required to make in excess of the principal amount of converted notes, as the case may be, with such offset and/or reduction subject to a cap price. If, however, the market price per ordinary share of IREN, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions. The capped call transactions will be solely cash settled unless certain conditions are satisfied.

No registration

The notes were only offered and sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any of IREN’s ordinary shares issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any of IREN’s ordinary shares issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction (including the United States and Australia) in which such offer, sale or solicitation would be unlawful.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the completion of the offering and the expected amount and intended use of the net proceeds. Forward-looking statements represent IREN’s current expectations, beliefs, and projections regarding future events and are subject to known and unknown uncertainties, risks, assumptions and contingencies, many of which are outside IREN’s control and that could cause actual results to differ materially from those described in or implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the closing conditions related to the offering and risks relating to IREN’s business, including those described in periodic reports that IREN files from time to time with the SEC. IREN cannot provide any assurances regarding its ability to effectively apply the net proceeds after funding the cost of entering into the capped call transactions as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and IREN does not undertake any obligation to update the forward-looking statements included in this press release for subsequent developments, except as may be required by law. For a further discussion of factors that could cause IREN’s future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in IREN’s Annual Report on Form 10-K for the year ended June 30, 2025 and other risks described in documents filed by IREN from time to time with the Securities and Exchange Commission.

About IREN

IREN is a leading developer, owner and operator of next-generation data centers powering the future of Bitcoin, AI and beyond utilizing 100% renewable energy including through the purchase of RECs. Strategically located in renewable-rich, fiber-connected regions across the U.S. and Canada, IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications.

• Power & Land Portfolio : 2,910MW of grid-connected power secured across >2,000 acres in the U.S. and Canada, with an additional multi-gigawatt development pipeline.
• Next-Generation Data Centers : 810MW of operating data centers underpinning three verticals: Bitcoin Mining, AI Cloud Services and AI Data Centers.
• Bitcoin Mining : one of the world’s largest and lowest-cost Bitcoin producers with 50 EH/s of installed self-mining capacity.
• AI Cloud Services : delivering high performance cloud compute to AI customers with next- generation GPUs.
• AI Data Centers : end-to-end design, construction and operation of data center infrastructure tailored for AI workloads.
  
  

Contacts

SOUTH JORDAN, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cricut, Inc. (“Cricut”) (NASDAQ: CRCT), the creative technology company that has brought a connected platform for making to millions of users worldwide, today announced it will report its financial results for the third quarter ended September 30, 2025 after the U.S. markets close on Tuesday, November 4, 2025. Cricut management will host a conference call and webcast to discuss the results that afternoon at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time).

A live webcast of the earnings call will be available on Cricut’s investor relations website at https://investor.cricut.com/ . A webcast replay will be available after the live event.

To access the audio call, please pre-register using this link: Cricut Q3 2025 Earnings Pre-Registration . After registering, a confirmation will be sent via email and will include dial-in details and a unique PIN code for entry to the call. To avoid long wait times, we suggest registering at least one day in advance or at minimum 15 minutes before the start of the call to receive your unique PIN code.

About Cricut, Inc.

Cricut, Inc. is a creative technology company that helps people lead creative lives. Cricut hardware and design software work together as a connected platform for consumers to make beautiful, high-quality DIY projects quickly and easily. These industry-leading products include a flagship line of smart cutting machines — the Cricut Maker ^® series, the Cricut Explore ^® series, Cricut Joy ^® , and Cricut Venture ^® — accompanied by other unique tools like Cricut EasyPress ^® , the Infusible Ink ^® system, and a diverse collection of materials. In addition to providing tools and materials, Cricut fosters a thriving community of millions of dedicated users worldwide.

Cricut has used, and intends to continue using, its investor relations website and the Cricut News Blog ( https://inspiration.cricut.com ) to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website and the Cricut News Blog in addition to following our press releases, SEC filings and public conference calls and webcasts.

Contacts:

Press
[email protected]

Investor Relations
Jim Suva
[email protected]

Source: Cricut, Inc.

NASHVILLE, Tenn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Healthcare Realty Trust Incorporated (NYSE:HR) today announced that on Thursday, October 30, 2025, after the market closes, it is scheduled to report results for the third quarter of 2025.

On October 31, 2025, at 9:00 a.m. Eastern Time, Healthcare Realty Trust is scheduled to hold a conference call to discuss earnings results, quarterly activities, general operations of the Company and industry trends. Simultaneously, a webcast of the conference call will be available to interested parties at www.healthcarerealty.com under the Investor Relations section. A webcast replay will be available following the call at the same address.

Conference Call Details
Domestic Dial-In Number: 1.800.715.9871, access code 4950066
International Dial-In Number: 1.646.307.1963, access code 4950066

Replay Conference Call Details
Domestic Dial-In Number: 1.800.770.2030, access code 4950066
International Dial-In Number: 1.609.800.9909, access code 4950066

Healthcare Realty Trust Incorporated (NYSE: HR) is the largest, pure-play owner, operator and developer of medical outpatient buildings in the United States.

Additional information regarding the Company can be found at www.healthcarerealty.com.

Ron Hubbard
Vice President, Investor Relations
P: 615.269.8175